Metabolic Engineering of Heterologous Pathways for Quillaic Acid Biosynthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The biological sources of quillaic acid (QA), a key component in the immunostimulatory adjuvant QS-21, are limited, and chemical synthesis is challenging due to its complex structure.
Innovation Solution
Engineering a heterologous biosynthetic pathway in host cells by expressing specific enzymes, such as β-amyrin synthase and CYP450 oxidases, to convert the universal precursor 2,3-oxidosqualene into quillaic acid, utilizing genes from Quillaja saponaria and other organisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chemical synthesis is used to produce quillaic acid, then the complex structure can be synthesized, but the synthesis process becomes challenging and inefficient
Solution Approach 1:
The patent replaces chemical synthesis methods with a biological system (metabolic engineering in heterologous host cells). The complex quillaic acid structure is produced through engineered enzymatic pathways rather than chemical reactions, substituting biological machinery for chemical manufacturing processes.
Solution Approach 2:
The patent divides the complex quillaic acid synthesis into discrete enzymatic steps, each catalyzed by a specific engineered enzyme. The pathway is segmented into sequential transformations from simple precursors to the final complex structure, making production manageable through modular biological components.
2Reliability
If biological sources are used to obtain quillaic acid, then natural production occurs, but the biological sources are limited
Solution Approach 1:
The patent creates a universal production platform using heterologous host cells (such as yeast or bacteria) that can be engineered to produce quillaic acid. This multi-functional system replaces the need for specific limited biological sources by enabling any suitable host to become a production factory through metabolic engineering.
Solution Approach 2:
The patent introduces intermediate enzymatic steps and precursor molecules into heterologous hosts. These intermediates serve as bridges between simple substrates available in host cells and the complex quillaic acid product, enabling production in organisms that do not naturally produce it.
3Adaptability or versatility
If heterologous biosynthetic pathway is engineered, then production in non-natural producers is enabled, but the pathway complexity increases
Solution Approach 1:
The patent segments the biosynthetic pathway into discrete enzymatic steps, each performed by a dedicated engineered enzyme. This modular approach allows complex quillaic acid synthesis to be distributed across multiple simple, well-characterized enzymatic reactions rather than requiring a single complex system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the production of quillaic acid in non-natural producers, facilitating the synthesis of QS-21 and overcoming the limitations of biological and chemical synthesis methods.
Implementation Method 1
an enzyme capable of oxidising β-amyrin or an oxidised derivative thereof at the C-28 position to a carboxylic acid
Implementation Method 2
an enzyme capable of oxidising β-amyrin or an oxidised derivative thereof such as echinocystic acid at the C-23 position to an aldehyde
Data Source
AI summary
The invention relates generally to materials and methods for biosynthesising quillaic acid in a host by expressing heterologous nucleotide sequences in the host each of which encodes a polypeptide which in combination have said QA biosynthesis activity. Example polypeptides include (i) a Beta-amyrin synthase; (ii) an enzyme capable of oxidising Beta-amyrin or an oxidised derivative thereof at the C-28 position to a carboxylic acid; (iii) an enzyme capable of oxidising Beta-amyrin or an oxidised derivative thereof at the C-16α position to an alcohol; and (iv) an enzyme capable of oxidising Beta-amyrin or an oxidised derivative thereof at the C-23 position to an aldehyde. Preferred nucleotide sequences are obtained from, or derived from, Q. saponaria.